Cramer's Morning Take: Eli Lilly & Bristol Myers 12/4/24

Discover the promising results of Eli Lilly's ZepBow, which outperformed competitors in weight loss trials. Delve into the optimistic future for both Eli Lilly and Bristol Myers as they navigate potential FDA decisions and innovative therapies. Explore investment predictions for a $50 stock with potential for significant gains and learn about educational opportunities to sharpen your business skills. Join the conversation for insightful market strategies and trends in the pharmaceutical sector.